Liang, Jingyuan http://orcid.org/0000-0002-3489-5776
Pylypchuk, Romana
Tang, Xun http://orcid.org/0000-0002-6990-0168
Shen, Peng
Liu, Xiaofei
Chen, Yi
Tan, Jing
Wu, Jinguo
Zhang, Jingyi
Lu, Ping
Lin, Hongbo
Gao, Pei http://orcid.org/0000-0001-8649-1290
Jackson, Rod http://orcid.org/0000-0001-5914-6934
Funding for this research was provided by:
Health Research Council of New Zealand (HRC 03/183, HRC 08/121, HRC VIEW 11/800 programme)
New Zealand Healthier Lives National Science Challenge (HL-T1CR-B)
National Key Research and Development Program of China (No.2020YFC2003503)
National Natural Science Foundation of China (81961128006, 81973132)
Beijing Natural Science Foundation (7182084)
Article History
Received: 20 January 2021
Accepted: 3 August 2021
First Online: 22 August 2021
Declarations
:
: Dr. Tang reported serving as a consultant for Medtronic. Dr. Gao reported serving as a consultant for Medtronic. No other disclosures were reported.
: The PREDICT study was approved by the Northern Region Ethics Committee in 2003 (AKY/03/12/314) with subsequent annual approval by the National Multi-region Ethics Committee since 2007 (MEC07/19/EXP). The CHERRY study was approved by the Peking University Institutional Review Board (IRB00001052-16011) in April 2016. The CREDENCE study was approved by the Peking University Institutional Review Board (IRB00001052-20086) in December 2020.
: Informed consent was not required for individuals included in the PREDICT T2D cohort as all information was anonymised; Participants in CHERRY T2D cohort were not required to provide informed consent as all of their information were routinely collected health data.
: Authors are responsible for the statements provided in the manuscript.